C
Curtis L. Scribner
Publications - 2
Citations - 412
Curtis L. Scribner is an academic researcher. The author has contributed to research in topics: Caspase 1 & AIM2. The author has an hindex of 2, co-authored 2 publications receiving 207 citations.
Papers
More filters
Journal ArticleDOI
OLT1177, a β-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation.
Carlo Marchetti,Benjamin J Swartzwelter,Fabia Gamboni,Charles Preston Neff,Katrin Richter,Tania Azam,Sonia Carta,Isak W. Tengesdal,Travis Nemkov,Angelo D'Alessandro,Curtis J. Henry,Gerald S. Jones,Scott A. Goodrich,Joseph P. St. Laurent,Terry M. Jones,Curtis L. Scribner,Robert B. Barrow,Roy D. Altman,Damaris B. Skouras,Marco Gattorno,Veronika Grau,Sabina Janciauskiene,Anna Rubartelli,Leo A. B. Joosten,Charles A. Dinarello,Charles A. Dinarello +25 more
TL;DR: It is demonstrated that OLT1177, an orally active β-sulfonyl nitrile molecule, inhibits activation of the NLRP3 inflammasome, with unique properties to reverse the metabolic costs of inflammation and to treat IL-1β– and IL-18–mediated diseases.
Journal ArticleDOI
Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: an open-label, dose-adaptive, proof-of-concept, phase 2a trial
Viola Klück,T.L.Th.A. Jansen,Matthijs Janssen,Antoaneta Comarniceanu,M. Efde,Isak W. Tengesdal,Kiki Schraa,Maartje C. P. Cleophas,Curtis L. Scribner,Damaris B. Skouras,Carlo Marchetti,Charles A. Dinarello,Charles A. Dinarello,Leo A. B. Joosten,Leo A. B. Joosten +14 more
TL;DR: Dapansutrile is a specific NLRP3 inflammasome inhibitor with a satisfactory safety profile and efficacy in the reduction of target joint pain in this study.